1,180 results match your criteria Buruli Ulcer

Development of an antibiotics delivery system for topical treatment of the neglected tropical disease Buruli ulcer.

Int J Pharm 2022 Jun 24:121954. Epub 2022 Jun 24.

ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal; 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Zona Industrial da Gandra, 4805-017 Barco, Guimarães, Portugal. Electronic address:

Skin infection by Mycobacterium ulcerans causes Buruli ulcer (BU) disease, a serious condition that significantly impact patient' health and quality of life and can be very difficult to treat. Treatment of BU is based on daily systemic administration of antibiotics for at least 8 weeks and presents drawbacks associated with the mode and duration of drug administration and potential side effects. Thus, new therapeutic strategies are needed to improve the efficacy and modality of BU therapeutics, resulting in a more convenient and safer antibiotic regimen. Read More

View Article and Full-Text PDF

Portable digital X-ray for TB pre-diagnosis screening in rural communities in Nigeria.

Public Health Action 2022 Jun;12(2):85-89

National Tuberculosis, Leprosy and Buruli Ulcer Control Program, Federal Ministry of Health Public Health, Abuja, Nigeria.

Setting: This pilot project was conducted in hard-to-reach communities of two Niger Delta States in the South-South Region of Nigeria.

Objective: To assess the usefulness of portable digital X-ray, the Delft-Light Backpack (DLB) for TB active case-finding (ACF) in hard-to-reach Niger Delta communities using the WHO 3B TB screening/diagnosis algorithm.

Design: DLB X-ray was used to screen all consenting eligible participants during community TB screening out-reaches in all hard-to-reach communities of Akwa Ibom and Cross River States in the Niger Delta, Nigeria. Read More

View Article and Full-Text PDF

[Control, elimination, eradication: Where do we stand with NTDs? Scientific day of the SFMTSI, 25 November 2021].

Med Trop Sante Int 2021 12 10;1(4). Epub 2021 Dec 10.

SFMTSI. Hôpital Pitié-Salpêtrière - Pavillon Laveran, 47-83 Boulevard de l'Hôpital, 75651 Paris cedex 13.

View Article and Full-Text PDF
December 2021

Evaluation of the Usability of a Mobile Application on Neglected Skin Diseases in Côte d'Ivoire: A Pilot Study.

Stud Health Technol Inform 2022 Jun;290:972-976

School of Public Health & Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.

This study investigated the usability of a mobile phone-based system, "eSkinHealth", for healthcare providers in Côte d'Ivoire. The eSkinHealth can be used both online and offline to address the poor Internet connectivity of these rural settings. Data recorded in the mobile application were synchronized with an online database, and specialists in Abidjan, Côte d'Ivoire and in Japan advised local healthcare providers on difficult cases. Read More

View Article and Full-Text PDF

What the snake leaves in its wake: Functional limitations and disabilities among snakebite victims in Ghanaian communities.

PLoS Negl Trop Dis 2022 05 23;16(5):e0010322. Epub 2022 May 23.

University of Groningen, Department of Internal Medicine/Infectious Diseases, University Medical Centre Groningen, Groningen, The Netherlands.

Background: The estimated five million snakebites per year are an important health problem that mainly affect rural poor populations. The global goal is to halve both mortality and morbidity from this neglected tropical disease by 2030. Data on snakebite morbidity are sparse and mainly obtained from hospital records. Read More

View Article and Full-Text PDF

Emerging threat of drug-resistant tuberculosis and trends in the era of COVID-19: A descriptive study from northwestern Nigeria.

J Clin Tuberc Other Mycobact Dis 2022 Aug 17;28:100319. Epub 2022 May 17.

Department of Medicine, College of Health Sciences, Bayero University, Kano, Nigeria.

Background: with resistance to first line and second line anti tuberculous drugs is a serious setback in the treatment of tuberculosis (TB). The COVID-19 pandemic constitutes a serious threat that could unwind the recent gains made thus far in the control of tuberculosis. This study aims to explore the pattern of drug resistant tuberculosis (DRTB) in our institution. Read More

View Article and Full-Text PDF

Neglected tropical diseases in Australia: a narrative review.

Med J Aust 2022 Jun 12;216(10):532-538. Epub 2022 May 12.

Australian National University, Canberra, ACT.

•Neglected tropical diseases (NTDs) represent a threat to the health, wellbeing and economic prosperity of billions of people worldwide, often causing serious disease or death. •Commonly considered diseases of low and middle-income nations, the presence of NTDs in high income countries such as Australia is often overlooked. •Seven of the 20 recognised NTDs are endemic in Australia: scabies, soil-transmitted helminths and strongyloidiasis, echinococcosis, Buruli ulcer, leprosy, trachoma, and snakebite envenoming. Read More

View Article and Full-Text PDF

Possum bites man: case of Buruli ulcer following possum bite.

Med J Aust 2022 05 20;216(9):452-453. Epub 2022 Apr 20.

University Hospital Geelong, Geelong, VIC.

View Article and Full-Text PDF

Mycobacterium ulcerans Experimental Dormancy.

Am J Trop Med Hyg 2022 Apr 11. Epub 2022 Apr 11.

Aix Marseille Univ., IRD, APHM, MEPHI, Marseille, France.

Whether Mycobacterium ulcerans, the etiological agent of Buruli ulcer in numerous tropical countries, would exist in a dormant state as reported for closely related Mycobacterium species, has not been established. Six M. ulcerans strains were exposed to a progressive depletion in oxygen for 2 months, using the Wayne model of dormancy previously described for M. Read More

View Article and Full-Text PDF

Induced Synthesis of Mycolactone Restores the Pathogenesis of and .

Front Immunol 2022 24;13:750643. Epub 2022 Mar 24.

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.

is the causative agent of Buruli ulcer (BU), the third most common mycobacterial infection. Virulent secretes mycolactone, a polyketide toxin. Most observations of infection are described as an extracellular milieu in the form of a necrotic ulcer. Read More

View Article and Full-Text PDF

Prediction of Epitopes in Virulence Proteins of for Vaccine Designing.

Curr Genomics 2021 Dec;22(7):512-525

Department of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura (U.P.), India.

Background: is the fundamental agent of the third most common Mycobacterial disease known as Buruli Ulcer (BU). It is an infection of the skin and soft tissue affecting the human population worldwide. Presently, the vaccine is not available against BU. Read More

View Article and Full-Text PDF
December 2021

A scope review on the global impact of COVID-19 lockdown on adolescents' health.

Afr Health Sci 2021 Dec;21(4):1518-1526

Federal Ministry of Agriculture and Rural development, Department of Veterinary and Pest Control Services.

Background: The implementation of COVID-19 lockdown measures across the globe could affect adolescents' health.

Objective: This review was conducted to assess the impact of the COVID-19 lockdown on the health of the adolescents.

Methodology: We conducted this study using the scope reviews methodological framework. Read More

View Article and Full-Text PDF
December 2021

Skin in the Game: An Assay to Monitor Leukocyte Infiltration in Dermal Lesions of a Guinea Pig Model for Tick-Borne Rickettsiosis.

Pathogens 2022 Jan 20;11(2). Epub 2022 Jan 20.

Comparative Biomedical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762, USA.

Intact, the skin typically serves as an effective barrier to the external world; however, once pathogens have breached this barrier via a wound, such as a tick bite, the surrounding tissues must recruit immune cells from the blood to neutralize the pathogen. With innate and adaptive immune systems being similar between the guinea pig and human systems, the ability of guinea pigs to show clinical signs of many infectious diseases, and the large size of guinea pigs relative to a murine model, the guinea pig is a valuable model for studying tick-borne and other pathogens that invade the skin. Here, we report a novel assay for assessing guinea pig leukocyte infiltration in the skin. Read More

View Article and Full-Text PDF
January 2022

The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer.

Front Immunol 2021 26;12:788146. Epub 2022 Jan 26.

Department of Microbial Sciences, School of Bioscience and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.

Buruli ulcer (BU), caused by , is a devastating necrotizing skin disease. Key to its pathogenesis is mycolactone, the exotoxin virulence factor that is both immunosuppressive and cytotoxic. The discovery that the essential Sec61 translocon is the major cellular target of mycolactone explains much of the disease pathology, including the immune blockade. Read More

View Article and Full-Text PDF
February 2022

Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β, are linked to fibrin formation in Buruli ulcer lesions.

PLoS Pathog 2022 01 31;18(1):e1010280. Epub 2022 Jan 31.

Department of Microbial Sciences, School of Bioscience and Medicine, University of Surrey, Guildford, United Kingdom.

Buruli ulcer (BU) is a neglected tropical disease caused by subcutaneous infection with Mycobacterium ulcerans and its exotoxin mycolactone. BU displays coagulative necrosis and widespread fibrin deposition in affected skin tissues. Despite this, the role of the vasculature in BU pathogenesis remains almost completely unexplored. Read More

View Article and Full-Text PDF
January 2022

Picturing health: Buruli ulcer in Ghana.

Lancet 2022 02 28;399(10327):786-797. Epub 2022 Jan 28.

Kumasi Centre for Collaborative Research in Tropical Medicine and School of Medicine and Dentistry, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

View Article and Full-Text PDF
February 2022

Mycobacterial skin infection.

Curr Opin Infect Dis 2022 04;35(2):79-87

University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy.

Purpose Of Review: The aim of this article is to review the most recent evidences concerning mycobacterial skin infections, limiting the period of literature research to 2020--2021.

Recent Findings: Mycobacterial skin infections include a heterogeneous group of cutaneous diseases.Cutaneous tuberculosis is usually the result of hematogenous dissemination or spread from underlying foci and it must be distinguished from tuberculids, resulting from the immunological reaction to Mycobacterium tuberculosis antigens. Read More

View Article and Full-Text PDF

The search for a Buruli Ulcer vaccine and the effectiveness of the Bacillus Calmette-Guérin vaccine.

Acta Trop 2022 Apr 20;228:106323. Epub 2022 Jan 20.

Discipline of Genetics, School of Life Sciences, University of KwaZulu-Natal, Westville, P/Bag X54001, Durban, South Africa. Electronic address:

Buruli Ulcer is a neglected tropical disease that is caused by Mycobacterium ulcerans. It is not fatal; however, it manifests a range of devastating symptoms on the hosts' bodies. Various drugs and treatments are available for the disease; however, they are often costly and have adverse effects. Read More

View Article and Full-Text PDF

Molecular Characterization of Mycobacterium ulcerans DNA Gyrase and Identification of Mutations Reducing Susceptibility to Quinolones .

Antimicrob Agents Chemother 2022 04 18;66(4):e0190221. Epub 2022 Jan 18.

Division of Bioresources, Hokkaido Universitygrid.39158.36 International Institute for Zoonosis Control, Sapporo, Japan.

Buruli ulcer disease is a neglected necrotizing and disabling cutaneous tropical illness caused by Mycobacterium ulcerans. Fluoroquinolone (FQ), used in the treatment of this disease, has been known to act by inhibiting the enzymatic activities of DNA gyrase. However, the detailed molecular basis of these characteristics and the FQ resistance mechanisms in M. Read More

View Article and Full-Text PDF

Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB).

Expert Opin Investig Drugs 2022 Feb 26;31(2):139-144. Epub 2022 Jan 26.

School of Biological Sciences, Nanyang Technological University, Singapore.

Introduction: Tuberculosis is an infectious disease that affected more than 50 million people and killed 6.7 million patients in the past 5 years alone. Additionally, rising incidence of treatment resistance threatens the global effort to eradicate this disease. Read More

View Article and Full-Text PDF
February 2022

Molecular and epidemiological characterization of recurrent Mycobacterium ulcerans infections in Benin.

PLoS Negl Trop Dis 2021 12 28;15(12):e0010053. Epub 2021 Dec 28.

Univ Angers, Inserm, INCIT, Angers, France.

Background: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans, an environmental mycobacterium. Although transmission of M. ulcerans remains poorly understood, the main identified risk factor for acquiring Buruli ulcer is living in proximity of potentially contaminated water sources. Read More

View Article and Full-Text PDF
December 2021

Correlation between Buruli Ulcer Incidence and Vectorborne Diseases, Southeastern Australia, 2000-2020.

Emerg Infect Dis 2021 12;27(12):3191-3192

Researchers have hypothesized that mosquitoes are vectors involved in Mycobacterium ulcerans transmission. Previous findings of a correlation between incidence of M. ulcerans, which causes Buruli ulcer, and locally acquired vectorborne diseases in southeastern Australia further strengthened this argument. Read More

View Article and Full-Text PDF
December 2021

Addressing constraints to informal providers' involvement in tuberculosis control: a qualitative study of patent medicine dealers and tuberculosis programme managers.

Glob Health Res Policy 2021 11 8;6(1):43. Epub 2021 Nov 8.

Department of Paediatrics, AE-FUTHA, Abakaliki, Ebonyi State, Nigeria.

Background: A major constraint to tuberculosis control is low case finding with under-reporting to national authorities. Evidence shows that Patent Medicine Dealers are first port of call for most people with symptoms of tuberculosis, yet there is poor referral of such clients to tuberculosis treatment facilities for further evaluation. This study investigated constraints to involvement of Patent Medicine Dealers in tuberculosis control. Read More

View Article and Full-Text PDF
November 2021

Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.

Antimicrob Agents Chemother 2022 01 18;66(1):e0087021. Epub 2021 Oct 18.

Swiss Tropical and Public Health Institutegrid.416786.a, Basel, Switzerland.

For the treatment of chronic wounds, acid-oxidizing solutions (AOSs) with broad-spectrum microbicidal activity without disturbing granulation tissue formation have been developed. We found AOSs to efficiently kill Mycobacterium ulcerans, the causative agent of Buruli ulcer, which is able to survive harsh decontamination treatments. Topical AOS treatment of Buruli ulcer lesions may support the recommended antibiotic therapy (oral rifampin and clarithromycin), prevent contamination of the environment by the mycobacteria, and control secondary infections, which are a prevalent wound management problem in resource-poor settings where Buruli ulcer is endemic. Read More

View Article and Full-Text PDF
January 2022

Chronic wounds in Sierra Leone: Searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital.

PLoS Negl Trop Dis 2021 10 13;15(10):e0009862. Epub 2021 Oct 13.

Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.

Background: Chronic wounds pose a significant healthcare burden in low- and middle-income countries. Buruli ulcer (BU), caused by Mycobacterium ulcerans infection, causes wounds with high morbidity and financial burden. Although highly endemic in West and Central Africa, the presence of BU in Sierra Leone is not well described. Read More

View Article and Full-Text PDF
October 2021

Determination of Bioenergetic Parameters in Mycobacterium ulcerans.

Methods Mol Biol 2022 ;2387:219-230

Lee Kong Chian School of Medicine, Experimental Medicine Building, Nanyang Technological University, Singapore, Singapore.

The oxidative phosphorylation (OxPhos) pathway has emerged as an attractive pathway for the development of anti-mycobacterial drugs. The OxPhos pathway is essential for ATP resynthesis and maintenance of the electrochemical transmembrane gradient. The bioenergetic parameters of the pathway such as oxygen consumption rate and ATP levels are quantifiable using current technology. Read More

View Article and Full-Text PDF
January 2022

Turbidity-Based MIC Assay and Characterization of Spontaneous Drug Resistant Mutants in Mycobacterium ulcerans.

Methods Mol Biol 2022 ;2387:209-217

Lee Kong Chian School of Medicine, Experimental Medicine Building, Nanyang Technological University, Singapore, Singapore.

Generation and characterization of drug resistant mutants is a powerful tool in antimicrobial drug discovery for identification of the molecular target of an investigational drug candidate. The method is relatively simple to be conducted in a classical microbiology laboratory. Its value has been augmented by the employment of next generation sequencing techniques to characterize single-nucleotide polymorphisms associated with drug resistance. Read More

View Article and Full-Text PDF
January 2022

Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

Methods Mol Biol 2022 ;2387:195-207

Center for TB Research, Johns Hopkins University, Baltimore, MD, USA.

Great progress has been made in understanding the pathogenesis and treatment of Buruli ulcer over the last 20 years. The rediscovery of the mouse footpad model of the disease with translation to clinical practice has changed treatment of this infectious disease, caused by Mycobacterium ulcerans, from surgery and skin grafting to the administration of antibiotics for 8 weeks or less with superior cure rates. Here we describe the development and enhancement of the mouse model during the last two decades. Read More

View Article and Full-Text PDF
January 2022

In Vitro Assessment of Drug Activity Against Mycobacterium ulcerans.

Methods Mol Biol 2022 ;2387:189-194

Center for TB Research, Johns Hopkins University, Baltimore, MD, USA.

As acknowledged by the Clinical and Laboratory Standards Institute (CLSI), there is an insufficient evidence base on which to recommend a standard method for antimicrobial susceptibility testing against M. ulcerans. The agar proportion method has been recognized as the standard method for susceptibility testing against Mycobacterium tuberculosis complex (MTBC) isolates for decades (Woods GL, Engenack NL, Lin G, Turnidge JD (2018) CLSI standards: guidelines for health care excellence. Read More

View Article and Full-Text PDF
January 2022